Tyrosine kinase inhibitor levels matter in treating chronic GVHD
Publication date
2019-07-01
Authors
van der Wagen, Lotte
Janssen, Julie
Raijmakers, Reinier
Clevers-Petersen, E.J.
de Witte, Moniek
de Jong, Niels
Bellido, Mar
Meijer, Ellen
Bär, Brigitte
Boelens, Jaap J.
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
No license information available
Abstract
We observed a possible concentration effect relationship for nilotinib on resolution of chronic Graft versus Host disease.These data suggest therapeutic drug monitoring might be useful for patients receiving tyrosine kinase inhibitors for chronic GVHD.
Keywords
Taverne, Hematology, Transplantation
Citation
van der Wagen, L, Janssen, J, Raijmakers, R, Petersen, E, de Witte, M, de Jong, N, Bellido, M, Meijer, E, Bär, B, Jan Boelens, J, Huitema, A & Kuball, J 2019, 'Tyrosine kinase inhibitor levels matter in treating chronic GVHD', Bone Marrow Transplantation, vol. 54, no. 7, pp. 1141-1144. https://doi.org/10.1038/s41409-018-0429-5